hOAT3 (SLC22A8)

The human organic anion transporter OAT3 (SLC22A8) is highly expressed at the basolateral membrane of proximal tubule cells in human kidneys, where it facilitates likewise OAT1 the first uptake step for renal secretion of a huge number of substrates. Preferentially, OAT3 mediate the transport of conjugated endogenous steroid hormones and several exogenous compounds like antibiotics, diuretics, NSAID (non-steroidal anti-inflammatory drugs), histamin-receptor2 blockers, antivirals, cytostatics and toxins. Therefore, the regulatory agencies decided that drugs eliminated significantly via the kidney have to be tested as potential inhibitors (substrates) for hOAT3.

Main localization:
Transporter assay:
Uptake transporter assay (potential inhibitors or substrates)
Probe substrates:
Probe inhibitors:
Indomethacin, probenecid
Regulatory relevance:
FDA and EMA guidance
Important interacting drugs:
Methotrexate, ochratoxin A, olmesartan, pitavastatin, pravastatin, rosuvastatin, probenecid, telmisartan, olmesartan, sulfasalazine, quinapril, ketoprofen, Losartan, furosemide, ibuprofen, indomethacin, bumetanide
From other species:
rOat3, mOat3

Concentration dependent inhibition of hOAT3-mediated 3H-ES uptake by the probe inhibitor indomethacin
Home | Services | Drug Transporter Assays | Drug Transporter | About us | News and Events | Contact | Imprint | Privacy Policy

PortaCellTec Biosciences GmbH • Science Park Va • Marie-Curie-Straße 8 • 37079 Göttingen • Germany • T. 0049 551 309 66440 • F. 0049 551 309 66442 •
info@portacelltec.de • © PortaCellTec Biosciences 2021